Protein C inhibitor.

abstract：:Rapid and accurate risk stratification is critical in determining the optimal treatment strategy for patients with acute pulmonary embolism (PE). Early identification of patients with normal blood pressure and a favorable prognosis (low-risk PE) might select a subset of patients for outpatient treatment, which is asso...

journal_title：Seminars in thrombosis and hemostasis

authors： Morillo R,Moores L,Jiménez D

更新日期：2017-07-01 00:00:00

abstract：:Anti-factor Xa methods have been generally accepted for the monitoring of heparin treatment mainly due to their sensitivity to LMWH and excellent performance on automated equipment. When such equipment is not available, as in small laboratories or on the night shift, there is a need for a simple manual method. In the ...

journal_title：Seminars in thrombosis and hemostasis

authors： Friberger P,Krig E,Eriksson-Skoog L,Svensson S,Isacson C

更新日期：1993-01-01 00:00:00

abstract：:With the continued accumulation of clinical and animal studies, it is becoming abundantly clear that the protein C anticoagulant pathway plays a critical role in the regulation of coagulation. Investigations also indicate that this pathway is intimately involved in the interaction of the coagulation and inflammatory s...

journal_title：Seminars in thrombosis and hemostasis

authors： Esmon NL,Esmon CT

更新日期：1988-04-01 00:00:00

abstract：:Coagulation factor XII (FXII), formerly known as Hageman factor, is a plasma glycoprotein which exerts a kaleidoscope of biological functions, including the initiation of the intrinsic pathway of blood coagulation, the activation of the kallikrein-kinin system, and the generation of bradykinin and angiotensin. The lar...

journal_title：Seminars in thrombosis and hemostasis

authors： Danese E,Montagnana M,Lippi G

更新日期：2016-09-01 00:00:00

abstract：:Measurement of D-dimer (fibrin degradation product) is important for determining not only the activation of fibrinolysis but also the severity of a hypercoagulable state. However, fibrin degradation products are in variable, and the reactivity to cross-linked fibrin degradation products produced during fibrin degradat...

journal_title：Seminars in thrombosis and hemostasis

authors： Matsuo T,Kobayashi H,Kario K,Suzuki S

更新日期：2000-01-01 00:00:00

abstract：:Coagulation management requires the balancing of different components that contribute to clot formation. These components include the interactions between platelets, procoagulant, anticoagulant, and fibrinolytic factors. The cause of bleeding or thrombotic events is often multifactorial; however, the tests clinicians ...

journal_title：Seminars in thrombosis and hemostasis

authors： Wegner J,Popovsky MA

更新日期：2010-10-01 00:00:00

abstract：:Anticoagulant therapy reduces deaths and disability in patients with or at risk of both arterial and venous thromboembolism. Highly effective antithrombotic therapies now exist that reduce the risk of both arterial thrombosis and venous thrombosis. Anticoagulant strategies include platelet inhibition, using a variety ...

journal_title：Seminars in thrombosis and hemostasis

authors： Goy J,Crowther M

更新日期：2012-10-01 00:00:00

abstract：:Cancer often leads to the activation of coagulation, manifesting as disseminated intravascular coagulation (DIC) in its most extreme form. DIC is characterized by systemic intravascular coagulation activation (leading to deposition of intravascular platelets and fibrin) and simultaneous consumption of coagulation prot...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M

更新日期：2019-06-01 00:00:00

abstract：:A prospective management decision analysis for the exclusion and diagnosis of pulmonary embolism (PE) based on pre-test clinical probability (PCP) estimation for PE, a rapid ELISA D-dimer test, perfusion lungscan (P-scan), CUS, spiral CT, and pulmonary angiography is proposed. The modified PCP model for PE of Wells et...

journal_title：Seminars in thrombosis and hemostasis

authors： Michiels JJ

更新日期：1998-01-01 00:00:00

abstract：:Recent evidence suggests that lupus anticoagulants are immunologically distinct from the anticardiolipin antibodies. Nevertheless, the associated clinical complications exhibited by the two groups of antibodies are similar. They have been shown to have a strong association with a history of arterial and venous thrombo...

journal_title：Seminars in thrombosis and hemostasis

authors： Kampe CE

更新日期：1994-01-01 00:00:00

abstract：:In the Netherlands, specialized care for patients with a bleeding disorder, including hemophilia, von Willebrand disease (VWD), and allied disorders, is concentrated in 13 Hemophilia Treatment Centers. The Dutch Hemophilia Treaters Society, the Dutch Hemophilia Nurses' Society, and the Netherlands Hemophilia Patients ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Wee EM,Leebeek FW,Eikenboom JC

更新日期：2011-07-01 00:00:00

abstract：:As the understanding of the genetic basis of the inherited thrombophilias has increased over recent years, their routine diagnostic genetic analysis has also matured. This review considers methods used to test for the factor V (F5) Leiden mutation and prothrombin 20210A (F2 c.*97G>A) allele, and analysis of the SERPIN...

journal_title：Seminars in thrombosis and hemostasis

authors： Cooper PC,Goodeve AC,Beauchamp NJ

更新日期：2012-09-01 00:00:00

abstract：:Hemophilia A (HA) and hemophilia B (HB) are rare congenital severe bleeding disorders, that may be controlled by proper administration of adequate prophylaxis with factor VIII (FVIII), and factor IX (FIX) concentrates, respectively, to prevent joint damage due to recurrent bleeding. However, approximately 30% of patie...

journal_title：Seminars in thrombosis and hemostasis

authors： Barg AA,Livnat T,Kenet G

更新日期：2018-09-01 00:00:00

abstract：:Clotting activation occurs frequently in cancer. Tissue factor (TF), the most potent initiator of coagulation, is expressed aberrantly in many types of malignancy and is involved not only in tumor-associated hypercoagulability but also in promoting tumor angiogenesis and metastasis via coagulation-dependent and coagul...

journal_title：Seminars in thrombosis and hemostasis

authors： Amirkhosravi A,Meyer T,Amaya M,Davila M,Mousa SA,Robson T,Francis JL

更新日期：2007-10-01 00:00:00

abstract：:Plasma-derived factor concentrates are important in the management of von Willebrand disease (VWD). We review the current literature regarding pharmacokinetic studies of von Willebrand factor (VWF) concentrates used to treat VWD. Using additional local experience of a crossover pharmacokinetic (PK) study comparing a c...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ,Kershaw G,McLachlan AJ,Lloyd J

更新日期：2007-11-01 00:00:00

abstract：: ...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ

更新日期：2019-02-01 00:00:00

abstract：:In order to assess inhibitor development in previously untreated patients (PUPs) with severe (factor VIII [FVIII]<1%) and moderate (FVIII 1 to 5%) hemophilia A, a prospective study was initiated in 1976. During the 23-year study period, 72 hemophiliacs were frequently exposed prophylactically or on demand to plasma-de...

journal_title：Seminars in thrombosis and hemostasis

authors： Kreuz W,Ettingshausen CE,Zyschka A,Oldenburg J,Saguer IM,Ehrenforth S,Klingebiel T

更新日期：2002-06-01 00:00:00

abstract：:Prophylactic treatment from ages 2 to 18 years could prevent the development of hemophilic arthropathy if the concentration of the patient's deficient factor is kept from falling below 1% of normal. Early treatment is of paramount importance because the immature skeleton is very sensitive to the complications of hemop...

journal_title：Seminars in thrombosis and hemostasis

authors： Rodriguez-Merchan EC

更新日期：2003-02-01 00:00:00

abstract：:In this article, three cases, with antithrombin (AT) abnormality "Toyama" (type IIb), AT abnormality "Aomori" (type IIa), and congenital AT deficiency (type I) with pregnancy and delivery managed with administration of both AT concentrates and low-molecular-weight heparin, are described. Additionally, a case of AT-pro...

journal_title：Seminars in thrombosis and hemostasis

authors： Sakuragawa N

更新日期：1997-01-01 00:00:00

abstract：:Disseminated intravascular coagulation (DIC) is a syndrome characterized by systemic intravascular activation of coagulation leading to widespread deposition of fibrin in the circulation. There is ample experimental and pathological evidence that the fibrin deposition contributes to multiple organ failure. The massive...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M,de Jonge E,van der Poll T,ten Cate H

更新日期：2001-12-01 00:00:00

abstract：:The articular problems of patients with hemophilia begin in infancy when minor injuries result in hemarthroses. Early continuous prophylaxis (from cradle to college) is of paramount importance because the immature skeleton is very sensitive to the complications of hemophilia; severe structural deficiencies may develop...

journal_title：Seminars in thrombosis and hemostasis

authors： Rodriguez-Merchan EC,Heim M

更新日期：2005-11-01 00:00:00

abstract：:Clinical and laboratory data of children with von Willebrand disease (VWD) types have been derived from retrospective studies and small case series. This article reports on the clinical and laboratory data of a large pediatric cohort in one single Argentinian center. The biological and clinical responses to desmopress...

journal_title：Seminars in thrombosis and hemostasis

authors： Bonduel M,Frontroth JP,Hepner M,Sciuccati G,Feliu-Torres A,Pieroni G

更新日期：2011-07-01 00:00:00

abstract：:While lupus anticoagulant (LA), anticardiolipin antibodies (aCL), anti-β2 glycoprotein I (anti-β2GPI) antibodies represent the best available and the most widely used tests in the investigation for antiphospholipid syndrome (APS), evidence gathered in recent years indicates that other antiphospholipid antibodies (aPL)...

journal_title：Seminars in thrombosis and hemostasis

authors： Bertolaccini ML,Sanna G

更新日期：2018-07-01 00:00:00

abstract：:We have explored the molecular basis of the clinical therapeutic effect of factor VIIa in hemophilia A using empirical reconstituted in vitro thrombin generation models. Tissue factor acts as a receptor and activator of preexistent but virtually inactive two-chain plasma factor VIIa. However, most of the factor VII ci...

journal_title：Seminars in thrombosis and hemostasis

authors： van't Veer C,Mann KG

更新日期：2000-01-01 00:00:00

abstract：:The extrinsic pathway is probably the predominant pathway in initiating blood coagulation in inflammatory lung diseases. Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor of factor VIIa/tissue factor in the presence of factor Xa. As it has been shown recently that TFPI plasma levels are increa...

journal_title：Seminars in thrombosis and hemostasis

authors： Cella G,Cipriani A,Tommasini A,Rampin E,Sbarai A,Rocconi R,Mazzaro G,Luzzatto G

更新日期：1997-01-01 00:00:00

abstract：:Bleeding typically results as a consequence of derangements of primary hemostasis, secondary hemostasis, or both, and can be dramatically amplified by the presence of other predisposing conditions, especially inherited bleeding disorders. Life-threatening hemorrhages are, however, almost exclusively caused by penetrat...

journal_title：Seminars in thrombosis and hemostasis

authors： Lippi G,Favaloro EJ,Cervellin G

更新日期：2013-02-01 00:00:00

abstract：:A prospective randomized double-blind trial was performed comparing conventional low-dose heparin with a LMWH fragment (Kabi 2165, Fragmin) for thromboprophylaxis in elective general abdominal surgical patients. The first dose of the fragment was given in the evening before surgery, and thereafter every evening. There...

journal_title：Seminars in thrombosis and hemostasis

authors： Bergqvist D,Burmark US,Frisell J,Guilbaud O,Hallböök T,Horn A,Lindhagen A,Ljungner H,Ljungström KG,Mätzsch T

更新日期：1990-10-01 00:00:00

abstract：:We experienced 23 cases of venous thrombosis after gynecological surgery for the past 12 years at Tokyo Women's Medical University Hospital, representing 0.345 % of all patients. Eighteen of the 23 cases had deep venous thrombosis (DVT) including five cases followed by pulmonary embolism (PE), and five cases had PE wi...

journal_title：Seminars in thrombosis and hemostasis

authors： Adachi T,Nakabayashi M,Takeda Y

更新日期：1998-01-01 00:00:00

abstract：:The beta2-glycoprotein I (beta2-GPI) is known for its procoagulant as well as anticoagulant properties. The influence of beta2-GPI on tissue factor (TF) activity was investigated by chromogenic assays for both factor Xa generation and factor VIIa activity. When 1.36 mg/mL beta2-GPI was added to phospholipids prior to ...

journal_title：Seminars in thrombosis and hemostasis

authors： Ieko M,Yasukouchi T,Sawada KI,Koike T

更新日期：1998-01-01 00:00:00

abstract：:Heparanase is an endo-β-glucuronidase that enzymatically cleaves heparan sulfates (HS) and heparan sulfate proteoglycan (HSPG) structures. Heparanase expression levels by tumors were correlated with cell invasion, angiogenic activity, and poor prognosis. Heparanase can also possess pro-tumorigenic effects independent ...

journal_title：Seminars in thrombosis and hemostasis

authors： Gerber U,Hoß SG,Shteingauz A,Jüngel E,Jakubzig B,Ilan N,Blaheta R,Schlesinger M,Vlodavsky I,Bendas G

更新日期：2015-03-01 00:00:00